Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4677470 | 0.84 | ALDH1A1 (0.50) | TSHRPOLBPTGS2LMNAGAA | |
| SCHEMBL28539380 | 0.77 | MAOB (0.53) | TSHRMAPK1NPSR1KMT2AMEN1 | |
| SCHEMBL6199944 | 0.69 | ALDH1A1 (0.42) | TSHRHDAC1HDAC6TDP1LMNA | |
| SCHEMBL10936307 | 0.69 | TSHR (0.53) | TSHRMAPK1NPSR1HDAC1HDAC6 | |
| SCHEMBL9339188 | 0.68 | GAA (0.53) | TSHRMAPK1NPSR1HDAC1HDAC6 | |
| SCHEMBL9339146 | 0.68 | TSHR (0.61) | TSHRMAPK1NPSR1HDAC1HDAC6 | |
| Nicotinyl Methylamide SCHEMBL30664356 | 0.67 | HDAC1 (0.69) | HDAC1HDAC6TDP1LMNAKMT2A | |
| Nicotinyl Methylamide SCHEMBL129458 | 0.67 | HDAC1 (0.69) | HDAC1HDAC6TDP1LMNAKMT2A | |
| Nicotinyl Methylamide SCHEMBL28560459 | 0.67 | HDAC1 (0.69) | HDAC1HDAC6TDP1LMNAKMT2A | |
| SCHEMBL6246677 | 0.67 | HDAC1 (0.69) | HDAC1HDAC6PTGS2TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015028395-A1 | DETERGENT AND CLEANING AGENTS HAVING IMPROVED PERFORMANCE | HENKEL AG & CO. KGAA (DE) | 2015-03-05 | — | — | WO | disclosed |
| EP-1474396-B9 | N-SUBSTITUTED3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICALS CONTAINING THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1474396-B1 | N-SUBSTITUTED3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICALS CONTAINING THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1474396-A4 | N-SUBSTITUTED3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICALS CONTAINING THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2006-01-18 | — | — | EP | disclosed |
| US-6932960-B2 | N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| US-6825204-B2 | FOR THERAPY OF DISEASES, SUCH AS PARASITIC AND VIRAL INFECTIONS, CONDITIONS ASSOCIATED WITH INFLAMMATION AND INFECTION, AND CONDITIONS MEDIATED BY CELL-PROLIFERATION OR COLLAGEN FORMATION; CONTRAST AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1474396-A2 | N-SUBSTITUTED3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICALS CONTAINING THEREOF | Bristol-Myers Squibb Company (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040176326-A1 | N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-09 | — | — | US | disclosed |
| US-20030170174-A1 | N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof | LANTHEUS MEDICAL IMAGING, INC. | 2003-09-11 | — | — | US | disclosed |
| WO-2003065991-A2 | N-SUBSTITUTED3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICALS CONTAINING THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176326-A1 | N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof | COL1A1, CD4, COL2A1 | TSHR 2675/4885MAPK1 1901/4885NPSR1 1337/4885 |
| US-20030170174-A1 | N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof | COL1A1, CD4, COL2A1 | TSHR 2675/4885MAPK1 1901/4885NPSR1 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.